Xenon Pharmaceuticals Inc. (XENE)
XENENASDAQ-GMBiotechnology: Pharmaceutical Preparations
$39.91
+0.2000 (+0.50%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $3.92bn
- P/E
- –
- EPS, last 4 quarters
- $-4.74
- Dividend yield
- –
- Day range
- –
- 52-week range
- $33.38 to $72.66
- Average volume
- 1.78m
- Previous close
- $39.71
Analysts
16 coveringBuy15 buy, 1 hold, 0 sell
Targets a year out average $69.75, +74.8% from here
Earnings
next estimate $-1.14Next report
Sep 2025
+0.9%
Dec 2025
-9.2%
Mar 2026
0.0%
Jun 2026
+4.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$96.34m | -$109.77m | -$112.33m | -$123.16m |
| Net income | -$90.90m | -$105.26m | -$102.30m | -$110.74m |
News
8 latest- Xenon Pharmaceuticals Inc. Reports Q3 2026 Financial Results and Business UpdateFintel · 3 hours ago
- Xenon Reports Promising Pain Data, Targets Phase 2 Trials For Two Drug Candidates RTTNews · Oct 29, 2026
- XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?Zacks · Oct 15, 2026
- Thursday 10/1 Insider Buying Report: XENE BNK Invest · Oct 1, 2026
- Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability ReviewMarketBeat · Sep 27, 2026
- Stocks Finish Mostly Higher as Crude Prices FallBarchart · Sep 21, 2026
- Stocks Waver as Bond Yields ClimbBarchart · Sep 18, 2026
- Stocks Mixed as Crude Oil Prices and Bond Yields RiseBarchart · Sep 18, 2026
The company
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon's lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- xenon-pharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.